Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

A new twist on value has investors waking up to the beauty of companies returning gobs of cash to shareholders.

We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Salesforce on Wednesday said former Gilead Sciences finance chief Robin Washington will join the software maker to become ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Gilead Sciences ( NASDAQ: GILD) is scheduled to announce Q4 earnings results on Tuesday, February 11th, after market close. Analysts expect a profit of $1.70 per share (-1.2% Y/Y) on revenue of $7.15B ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...